CARD17

Across TCGA pan-cancer cohorts, CARD17 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of CARD17’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CARD17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CARD17 is over-expressed in tumor.

KIRC, LUSC, and HNSC are the cancer types where CARD17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CARD17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	+0.461	<.001	11	view →
LUSC	Male	All	+1.436	<.001	6	view →
HNSC	All	All	+0.787	.005	6	view →
BRCA	All	II,III,IV	+0.597	<.001	6	view →
LUAD	Female	All	+0.754	<.001	5	view →
LIHC	All	All	+0.122	.023	5	view →
BLCA	Male	All	+0.828	.022	3	view →
THCA	Male	IV	+0.380	.010	3	view →
KIRP	All	All	+0.086	.023	2	view →
STAD	Female	III,IV	+1.450	.021	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

CARD17–KIRC

Open the KIRC breakdown →